Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda

AIDS Research and Human Retroviruses

Volumn 28, Issue 12, 2012, Pages 1739-1744

  Reynolds, Steven J ^a,b   Laeyendecker, Oliver ^a,b   Nakigozi, Gertrude ^c   Gallant, Joel E ^b   Huang, Wei ^d   Hudelson, Sarah E ^b   Quinn, Thomas C ^a,b   Newell, Kevin ^e   Serwadda, David ^f   Gray, Ronald H ^g   Wawer, Maria J ^g   Eshleman, Susan H ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RAKAI HEALTH SCIENCES PROGRAM   (Uganda)

^d MONOGRAM BIOSCIENCES   (United States)

^e SAIC FREDERICK INC   (United States)

^f MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; UGANDA; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; UGANDA; YOUNG ADULT;

EID: 84870017526     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0352     Document Type: Article

References (19)

1. AIDS Control Program Uganda Ministry of Health. The Status of Antiretroviral Therapy in Uganda as of December 2010-Update. 2011.
2. Calmy A, Ford N, Hirschel B, et al.: HIV viral load monitoring in resource-limited regions: Optional or necessary? Clin Infect Dis 2007;44(1):128-134.
3. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al.: The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009;23(9):1127-1134.
4. Mee P, Fielding KL, Charalambous S, Churchyard GJ, and Grant AD: Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008;22(15):1971-1977.
5. Reynolds SJ, Nakigozi G, Newell K, et al.: Failure of im-munologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009;23(6):697-700.
6. Schooley RT: Viral load testing in resource-limited settings. Clin Infect Dis 2007;44(1):139-140.
7. Hamers RL, Wallis CL, Kityo C, et al.: HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: A multicentre observational study. Lancet Infect Dis 2011;11(10):750-759.
8. Muwonga J, Edidi S, Butel C, et al.: Resistance to anti-retroviral drugs in treated and drug-naive patients in the Democratic Republic of Congo. J Acquir Immune Defic Syndr 2011;57(Suppl 1):S27-S33.
9. Ndembi N, Hamers RL, Sigaloff KC, et al.: Transmitted an-tiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS 2011;25(7):905-910.
10. Eshleman SH, Laeyendecker O, Parkin N, et al.: Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. AIDS 2009;23(7):845-852.
11. Johnson VA, Calvez V, Gunthard HF, et al.:2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011;19(4):156-164.
12. Flandre P, Chappey C, Marcelin AG, et al.: Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection. J Infect Dis 2007;195(3):392-398.
13. Rozanov M, Plikat U, Chappey C, Kochergin A, and Tatusova T: A web-based genotyping resource for viral sequences. Nucleic Acids Res 2004;32(Web Server issue):W654-W659.
14. El-Khatib Z, Ekstrom AM, Ledwaba J, et al.: Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: A cross-sectional study in Soweto, South Africa. AIDS 2010;24(11):1679-1687.
15. Johannessen A, Naman E, Kivuyo SL, et al.: Virological efficacy and emergence of drug resistance in adults on anti-retroviral treatment in rural Tanzania. BMC Infect Dis 2009;9:108.
16. Reynolds S, Sendagire H, Newell K, Castelnuovo B, Kiragga A, Namugga I, et al.: Routine VLM reduces the rate of accumulated genotypic resistance to commonly used ART in Uganda. Abstract 53, 18th Conference on Retroviruses and Opportunistic Infections, 2011.
17. Reynolds SJ, Kityo C, Mbamanya F, et al.: Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. Antivir Ther 2009;14(2):293-297.
18. Eshleman SH, Jones D, Galovich J, et al.: Phenotypic drug resistance patterns in subtype A HIV-1 clones with non-nucleoside reverse transcriptase resistance mutations. AIDS Res Hum Retroviruses 2006;22(3):289-293.
19. Shafer RW, Rhee SY, and Bennett DE: Consensus drug resistance mutations for epidemiological surveillance: Basic principles and potential controversies. Antivir Ther 2008; 13(Suppl 2):59-68.